Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferons and multiple sclerosis.

M Clanet1, A Blancher, P Calvas

  • 1Service de Neurologie, CHU Purpan, Toulouse, France.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Parkinson's Disease, Speech and Neurosurgery.

Brain and behavior·2025
Same author

Body mass index variations in patients with Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion: A case control study versus standard of care and subthalamic nucleus deep brain stimulation.

Revue neurologique·2021
Same author

Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study.

Parkinsonism & related disorders·2020
Same author

European survey on national training activities in clinical research.

Trials·2019
Same author

A totally data-driven whole-brain multimodal pipeline for the discrimination of Parkinson's disease, multiple system atrophy and healthy control.

NeuroImage. Clinical·2019
Same author

Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions.

European journal of neurology·2019
Same journal

Corrigendum to "Ruyiping extract reduces lung metastasis in triple negative breast cancer by regulating macrophage polarization" [Biomed. Pharmacother. 141 (2021) 111883].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Microfluidic human liver slices reveal antifibrotic effects of liraglutide via HSC deactivation and ECM remodeling.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Corrigendum to "Targeting PD-L1 and disrupting Siglec-9 cooperatively potentiate macrophage phagocytosis of breast cancer via a trispecific macrophage engager (TriME)" [Biomed. Pharmacother. 200 (2026), 119609].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Targeted attenuation of liver fibrosis using microbubble-enhanced protease-activated receptor 1 chimeric antigen receptor T cells.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Euphol targets key oncogenic processes and promotes chemoprevention in organoid and In Vivo models of colorectal cancers.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

CAR-T cell therapy and oncolytic viruses: A synergic approach for advanced GI cancers.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
See all related articles

Interferons (IFNs) modulate immune responses in Multiple Sclerosis (MS). While IFN gamma worsens lesions, IFN alpha/beta may offer therapeutic benefits by regulating immune reactions in the central nervous system.

Area of Science:

  • Neuroimmunology
  • Immunology
  • Cell Biology

Background:

  • Multiple Sclerosis (MS) is a central nervous system (CNS) disease characterized by immune-mediated inflammatory demyelination.
  • Interferons (IFNs) are crucial proteins with antiviral, antitumoral, and immunomodulatory functions.
  • IFNs are present in active MS lesions, suggesting a role in disease pathogenesis.

Purpose of the Study:

  • To investigate the role and localization of different Interferon (IFN) subtypes in Multiple Sclerosis (MS) lesions.
  • To analyze the impact of IFN gamma and IFN alpha/beta on immune reactions within the CNS in MS.
  • To evaluate the therapeutic potential of IFNs in MS based on existing clinical trials.

Main Methods:

  • Immunohistochemical analysis of IFN localization in MS lesions.

Related Experiment Videos

  • Assessment of immune cell activity, including Natural Killer (NK) cells.
  • Review and discussion of therapeutic trials involving IFN gamma and IFN alpha/beta in MS patients.

    • Main Results:

    • IFN gamma localized on astrocytes may enhance immune reactions by increasing Ia antigen expression.
    • IFN alpha/beta found on microglial cells and astrocytes might limit lesion progression.
    • MS patients often exhibit impaired NK cell activity and reduced IFN production, indicating immune dysregulation.

    Conclusions:

    • IFN gamma demonstrates a detrimental effect in MS therapeutic trials.
    • IFN alpha/beta warrants further investigation for potential beneficial effects in MS treatment.
    • Understanding IFN roles is critical for developing targeted immunomodulatory therapies for MS.